Fluorodeoxyglucose F18

PreclinicalRadiopharmaceutical

UUniversity of California, San Francisco

Fluorodeoxyglucose F18 is one of 50 small molecule programs targeting Metastatic Cancer. It is currently in Preclinical.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Metastatic CancerActive, not recruiting

MPARecruiting

Metastatic CancerPreclinical

Active, not recruiting

MPAPreclinical

Recruiting

Competition

Competitive Landscape

48 competitors in MPA

#DrugCompanyPhaseTrials

Repatha

Amgen

Approved

2 2

Activella

Eli Lilly

Approved

2 3

Tremfya

Johnson & Johnson

Approved

1 4

Jardiance

Boehringer Ingelheim

Approved

2 5

Rituxan

Roche

Phase 3

3 6

Nitrostat

VViatris Specialty LLC

Phase 2

2 7

Obicetrapib

NNewAmsterdam Pharma

Phase 2

1 8

Heparin Sodium

BBaxter Healthcare Corporation

Phase 1

2 9

XTR004

SSinotau Pharmaceutical Group

Phase 3

1 10

Uloric

Takeda

Preclinical

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q2 2029

PreclinicalActive, not recruiting

Metastatic Cancer

NCT06630845

Clinical

Trials by Indication[1]

Metastatic Cancer1 trial

Comparison of Whole Body DWI to FDG PET Using PET/MRI

Active, not recruiting·UUniversity of California, San Francisco·Preclinical·NCT06630845·25 enrolled

Sources

References

[1]
ClinicalTrials.gov — 1 trial record for Fluorodeoxyglucose F18. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Fluorodeoxyglucose F18 compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Fluorodeoxyglucose F18. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — University of California, San Francisco company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Radiopharmaceutical[2]
Highest Phase: Preclinical[1]
Company: UUniversity of California, San Francisco

Fluorodeoxyglucose F18

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q2 2029

Trials by Indication[1]

Metastatic Cancer1 trial

References

Drug Info

Quick Facts

Related News